Literature DB >> 20350656

Rituximab: therapeutic benefit! Vitamin R?

Clifton Mo1, Berengere Vire, Adrian Wiestner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20350656      PMCID： PMC2848175          DOI： 10.1053/j.seminhematol.2010.02.003

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  6 in total

1.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

2.  Rituximab dose-escalation trial in chronic lymphocytic leukemia.

Authors:  S M O'Brien; H Kantarjian; D A Thomas; F J Giles; E J Freireich; J Cortes; S Lerner; M J Keating
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.

Authors:  Paul V Beum; Adam D Kennedy; Michael E Williams; Margaret A Lindorfer; Ronald P Taylor
Journal:  J Immunol       Date:  2006-02-15       Impact factor: 5.422

4.  Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Authors:  Michael E Williams; John J Densmore; Andrew W Pawluczkowycz; Paul V Beum; Adam D Kennedy; Margaret A Lindorfer; Susan H Hamil; Jane C Eggleton; Ronald P Taylor
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

5.  Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.

Authors:  Georg Aue; Margaret A Lindorfer; Paul V Beum; Andrew W Pawluczkowycz; Berengere Vire; Thomas Hughes; Ronald P Taylor; Adrian Wiestner
Journal:  Haematologica       Date:  2009-08-13       Impact factor: 9.941

6.  Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

Authors:  David Daydé; David Ternant; Marc Ohresser; Stéphanie Lerondel; Sabrina Pesnel; Hervé Watier; Alain Le Pape; Pierre Bardos; Gilles Paintaud; Guillaume Cartron
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113
  6 in total
  2 in total

1.  Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

Authors:  Suresh Veeramani; Siao-Yi Wang; Christopher Dahle; Sue Blackwell; Laura Jacobus; Tina Knutson; Anna Button; Brian K Link; George J Weiner
Journal:  Blood       Date:  2011-07-18       Impact factor: 22.113

Review 2.  Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

Authors:  Timothy M Pierpont; Candice B Limper; Kristy L Richards
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.